Lynnetta M. Watts

3.4k total citations · 1 hit paper
27 papers, 2.6k citations indexed

About

Lynnetta M. Watts is a scholar working on Molecular Biology, Immunology and Surgery. According to data from OpenAlex, Lynnetta M. Watts has authored 27 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Immunology and 6 papers in Surgery. Recurrent topics in Lynnetta M. Watts's work include Protein Tyrosine Phosphatases (3 papers), Immune Cell Function and Interaction (3 papers) and Immune Response and Inflammation (3 papers). Lynnetta M. Watts is often cited by papers focused on Protein Tyrosine Phosphatases (3 papers), Immune Cell Function and Interaction (3 papers) and Immune Response and Inflammation (3 papers). Lynnetta M. Watts collaborates with scholars based in United States, Germany and Austria. Lynnetta M. Watts's co-authors include Sanjay Bhanot, Brett P. Monia, Robert A. McKay, Sheri Booten, Sanjay K. Pandey, Mark J. Graham, C. Frank Bennett, Stephanie Propp, Susan M. Freier and Scott Davis and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Diabetes Care.

In The Last Decade

Lynnetta M. Watts

27 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting

2006 1.7k citations Christine Esau, Scott Davis et al. Cell Metabolism profile →

Peers

Countries citing papers authored by Lynnetta M. Watts

Since Specialization

Citations

This map shows the geographic impact of Lynnetta M. Watts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynnetta M. Watts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynnetta M. Watts more than expected).

Fields of papers citing papers by Lynnetta M. Watts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynnetta M. Watts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynnetta M. Watts. The network helps show where Lynnetta M. Watts may publish in the future.

Co-authorship network of co-authors of Lynnetta M. Watts

This figure shows the co-authorship network connecting the top 25 collaborators of Lynnetta M. Watts. A scholar is included among the top collaborators of Lynnetta M. Watts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynnetta M. Watts. Lynnetta M. Watts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial 2023 ·Journal of clinical lipidology ·Joseph L. Witztum, Daniel Gaudet, (unknown), (unknown), Handrean Soran, Ioanna Gouni‐Berthold, (unknown), (unknown), Richard H. Jones, Lynnetta M. Watts, Shuting Xia, Sotirios Tsimikas	24
2	Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study 2022 ·Journal of clinical lipidology ·Elif A Oral, Abhimanyu Garg, Joseph A. Tami, (unknown), Louis O’Dea, H Schmidt, Anatoly Tiulpakov, Ann Mertens, Veronica J. Alexander, Lynnetta M. Watts, Eunju Hurh, Joseph L. Witztum, Richard S. Geary, Sotirios Tsimikas	47
3	Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers 2020 ·Nucleic Acid Therapeutics ·Lynnetta M. Watts, Ewa Karwatowska‐Prokopczuk, Eunju Hurh, Veronica J. Alexander, (unknown), Louis O’Dea, Richard S. Geary, Sotirios Tsimikas	3
4	Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial 2020 ·The Lancet. Gastroenterology & hepatology ·Rohit Loomba, Erin Morgan, Lynnetta M. Watts, Shuting Xia, (unknown), Richard S. Geary, Brenda F. Baker, Sanjay Bhanot	80
5	Efficacy and safety of volanesorsen for the treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study 2020 ·Endocrine Abstracts ·Louis O’Dea, Joseph A. Tami, Veronica J. Alexander, Lynnetta M. Watts, Eunju Hurh, (unknown), Hartmut Schmidt, Anatoly Tiulpakov, Ann Mertens, Abhimanyu Garg, (unknown)	4
6	Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy 2019 ·Diabetes Care ·Erin Morgan, Bruce L. Tai, Nguyen C. Pham, (unknown), Lynnetta M. Watts, (unknown), Shiangtung W. Jung, Martin Gajdošík, Martin Krššák, Michael Krebs, Richard S. Geary, Brenda F. Baker, Sanjay Bhanot	42
7	Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes 2018 ·Diabetes Care ·Andrés Digenio, Nguyen C. Pham, Lynnetta M. Watts, Erin Morgan, Shiangtung W. Jung, Brenda F. Baker, Richard S. Geary, Sanjay Bhanot	39
8	Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model 2017 ·Journal of Pharmacokinetics and Pharmacodynamics ·Kenneth T. Luu, Erin Morgan, Sanjay Bhanot, Richard S. Geary, (unknown), Claudette Bethune, Lynnetta M. Watts, Scott P. Henry, Yanfeng Wang	11
9	Peripheral Reduction of FGFR4 with Antisense Oligonucleotides Increases Metabolic Rate and Lowers Adiposity in Diet-Induced Obese Mice 2013 ·PLoS ONE ·Xing Yu, Lynnetta M. Watts, Vara Prasad Manchem, Kaushik Chakravarty, Brett P. Monia, Michael L. McCaleb, Sanjay Bhanot	25
10	Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice 2008 ·American Journal of Physiology-Endocrinology and Metabolism ·Xing Yu, Susan F. Murray, Lynnetta M. Watts, Sheri Booten, (unknown), Brett P. Monia, Sanjay Bhanot	27
11	Reduction of Low Molecular Weight Protein-tyrosine Phosphatase Expression Improves Hyperglycemia and Insulin Sensitivity in Obese Mice 2007 ·Journal of Biological Chemistry ·Sanjay K. Pandey, Xing Yu, Lynnetta M. Watts, M. Dodson Michael, Kyle W. Sloop, (unknown), (unknown), Vara Prasad Manchem, (unknown), Robert A. McKay, Brett P. Monia, Sanjay Bhanot	61
12	miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting breakdown → 2006 ·Cell Metabolism ·Christine Esau, Scott Davis, Susan Murray, Xing Yu, Sanjay K. Pandey, (unknown), Lynnetta M. Watts, Sheri Booten, Mark J. Graham, Robert A. McKay, (unknown), Stephanie Propp, Bridget Lollo, Susan M. Freier, C. Frank Bennett, Sanjay Bhanot, Brett P. Monia	1717
13	Antisense oligonucleotides targeted against glucocorticoid receptor reduce hepatic glucose production and ameliorate hyperglycemia in diabetic mice 2005 ·Metabolism ·Yin Liang, Melville C. Osborne, Brett P. Monia, Sanjay Bhanot, Lynnetta M. Watts, Pengxiang She, (unknown), Xiaoli Chen, Keith T. Demarest	36
14	Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism 2005 ·Diabetes ·Lynnetta M. Watts, Vara Prasad Manchem, (unknown), (unknown), Robert A. McKay, Dingjiu Bao, (unknown), Brett P. Monia, Diane Bodenmiller, (unknown), Hongyan Zhang, Amy L. Cox, Steven J. Jacobs, (unknown), Kyle W. Sloop, Sanjay Bhanot	111
15	Measurement of radiographic changes in adjuvant-induced arthritis in rats by quantitative image analysis 1995 ·Arthritis & Rheumatism ·Ronald E. Esser, (unknown), (unknown), Lynnetta M. Watts, Mark D. Murphey, (unknown)	24
16	The Importance of DR4Dw4 β Chain Residues 70, 71, and 86 in Peptide Binding and T Cell Recognition 1995 ·Cellular Immunology ·Kathy L. Signorelli, Lynnetta M. Watts, Laurie E. Lambert	13
17	Thy 1+ donor cells function as veto cells in the maintenance of tolerance across a major histocompatibility complex disparity in mixed-lymphoid radiation chimeras. 1993 ·PubMed ·George E. Pierce, Lynnetta M. Watts	16
18	Peptidyl fluoromethyl ketones as inhibitors of cathepsin B 1992 ·Biochemical Pharmacology ·Nahed K. Ahmed, (unknown), Lynnetta M. Watts, (unknown), Larry P. Thornburg, (unknown), Ronald E. Esser	46
19	SUBLETHAL FRACTIONATED TOTAL-BODY IRRADIATION AND DONOR BONE MARROW INFUSION FOR INDUCTION OF ALLOGRAFT TOLERANCE 1985 ·Transplantation ·George E. Pierce, Lynnetta M. Watts, John Clancy	13
20	Evidence for graft-versus-host disease in total-lymphoid-irradiated recipients of allogeneic bone marrow and skin grafts 1981 ·Journal of Surgical Research ·George E. Pierce, Lynnetta M. Watts, (unknown), James H. Thomas	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact